Projets réalisés

Regenosca is addressing a significant challenge in soft tissue repair, particularly in the field of urogynecology.

The primary challenge lies in the current methods for treating conditions like urethral stricture, pelvic organ prolapse (POP), and prostatectomy. These procedures often involve autologous tissue grafts or synthetic meshes, both of which come with limitations such as the need for additional surgical sites, long recovery times, high complication risks, and recurrence rates. 

The main objective of this project is to develop an innovative single-use mold system for Regenosca’s TissueSpan platform—a bioabsorbable mesh that fosters soft tissue regeneration without requiring a second surgical site. TissueSpan facilitates the body’s natural healing by attracting the patient’s own cells upon implantation. This process reduces the risks linked to traditional treatments and accelerates recovery, especially in urogynecology procedures. By creating a new mold system for mesh manufacturing, the project seeks to streamline production, enhancing scalability, safety, and efficiency. The development of this system will leverage the expertise of HEIA-FR, specifically the Institute of Applied Plastic Research and the Biofactory Competence Center. The industrial partners will provide critical application-oriented insights and support the co-development of scalable processes. Their involvement ensures the alignment of research outcomes with real-world manufacturing requirements, thereby laying a robust foundation for future industrial production.

The anticipated results of the project include a refined manufacturing process that ensures smoother integration into certified cleanroom environments. The new single-use molding system will reduce the risk of operator errors, minimize contamination, and ensure that the meshes are produced with high consistency and quality. Furthermore, Regenosca will be ready to begin clinical trials, bringing TissueSpan one step closer to becoming a market-ready product. This will allow Regenosca to move forward with regulatory approvals and clinical applications, enhancing its position in the medical device sector. 

The impact of the project goes beyond Regenosca. For its industry partners—Mecaplast, Medistri, and Confinis—the development of the innovative mold system and the successful integration of TissueSpan into clinical trials will significantly strengthen their product portfolios. These advancements will lay the groundwork for long-term collaboration, ensuring continued activities even after the project’s completion. As Regenosca scales and approaches market entry, the foundation established through this project can expand into other areas, such as cleanroom manufacturing, laboratory testing for technical file content, and more. This collaborative effort will accelerate innovation and contribute to the growth of the medical device sector, particularly within the canton’s thriving economy.